Abstract
Introduction
In the present work we investigated whether these compounds overcame the Pgp activity at BBB 68 and GB levels. We used human brain microvascular endothelial cells and GB cells obtained from (neurospheres, NS) cultures. In isolated BBB and GB, as well as in co-culture systems, we studied 71 the effects of Pgp ligands on the transport and accumulation on doxorubicin, chosen as a 72 prototypical drug that does not cross BBB [12, 22] and is ineffective against GB NS [16] , being a Briefly, the commercially available 4'-hydroxybiphenyl-4-carboxylic acid 7 was converted into the 86 corresponding methyl ester by refluxing in methanol with a catalytic amount of concentrated 87 sulfuric acid. The product was reduced to the benzyl alcohol 9 in presence of LiAlH4 at room 88 temperature. Treatment of 9 with 37% HCl at 90 °C afforded the benzyl chloride 10 which was 89 readily reacted with 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride to give MC70. In preliminary dose-dependent experiments, we verified the lack of toxicity of the compounds on -but not compounds 4-6 -significantly increased the delivery of doxorubicin, a virtually BBB-99 impermeable drug [12, 22] , through hCMEC/D3 cells monolayer ( Figure 1C) . The permeability of 100 mitoxantrone, an index of BCRP activity [12] , was not affected (Supplementary Figure 1) .
90

Pgp ligands increase the delivery of doxorubicin across BBB monolayer
101
Doxorubicin is also a substrate of MRP1 and BCRP; indeed, doxorubicin delivery across previous findings [12, [22] [23] [24] , suggesting the functional integrity of the BBB monolayer. None of 129 the compounds changed the TEER of BBB monolayer a 1 nM, while at 100 nM compounds 1-3
130
decreased TEER values indicating the loss of BBB integrity at these concentrations ( We next validated the efficacy of our compounds against primary GB cells of 3 patients. From each 143 tumor, AC and NS were generated (Figure 2A) . As previously shown [16] Figure 3A ), indicative of cell damage and necrosis [16] , they did not activate 162 caspase 3 (Figure 3B ), an index of apoptosis, and they did not reduce AC and NS viability ( Figure   163 3C). According to the higher retention of doxorubicin in AC than in NS, the drug increased LDH doxorubicin delivered into NS ( Figure 4A ) was unable to elicit cell necrosis ( Figure 4B ) and 176 apoptosis ( Figure 4C ), nor to decrease NS viability ( Figure 4D ). The co-incubation with 177 compounds 1-3 significantly increased the amount of doxorubicin delivered to NS (Figure 4A ), the 178 release of LDH ( Figure 4B ) and the activity of caspase 3 ( Figure 4C ). At longer time-point NS 179 viability was also reduced by the co-incubation of doxorubicin and compounds 1-3 ( Figure 4D ). containing BBB. After 3 h, the medium of the lower chamber was collected: part was added to on 185 NS cultures ( Figure 5A ), part was used to measure the doxorubicin concentration ( Figure 5B ). The 186 drug concentration in the media of the lower chamber ranged between 1 and 1.8 μM for the
187
Transwells treated with compounds 1-3, and was significantly higher than in all the other 188 experimental conditions ( Figure 5B ). The effects elicited by the media derived from these
189
Transwells was compared with the effects produced by medium containing 1 μM doxorubicin. Of 190 note, the intracellular doxorubicin uptake in NS ( Figure 5C ), the release of LDH ( Figure 5D ), the 191 activity of caspase-3 ( Figure 5E ) were higher, the viability of NS was lower ( Figure 5F ) when NS
192
were treated with media derived from Trasnwells exposed to compounds 1-3 than with medium chemosensitizing efficacy of Pgp-reversing agents in GB and BBB-GB co-cultures (12, 13, 16 Lakes, NJ). The electrophoresis reagents were obtained from Bio-Rad Laboratories (Hercules, CA).
318
The protein content of cell lysates was assessed with the BCA kit from Sigma Chemicals Co. (St.
319
Louis, MO). Unless specified otherwise, all reagents were purchased from Sigma Chemicals Co.
320
Synthesis and characterization of compounds. 1 H and 13 C-NMR spectra were recorded on a Jeol Technology, Milano, Italy), were measured as previously described [12, [22] [23] [24] (lucifer yellow). Fluorescence was converted in nmol/cm 2 , using a calibration curve previously set.
390
The autofluorescence of the medium, considered as a blank, was subtracted from each measure. The 391 permeability coefficients were calculated according to [36] . conditions for doxorubicin transport assay were carried out as reported in [37] .
395
GB cells. Primary human GB cells (01010627, CV17, Nov3, here identified as "patients 1, 2 and University of Torino (ORTO11WNST). The histological diagnosis was performed according to
401
WHO guidelines. Cells were cultured as adherent cells (AC) or neurospheres (NS) as previously 402 described [38] , with minor modifications [16] . Phenotypic characterization of differentiation and 403 stemness markers, in vitro clonogenicity and self-renewal, in vivo tumorigenicity are detailed in 404 [16] . Morphological analysis was performed with a bright field microscope (Leica Microsystems,
405
Wetzlar, Germany). For phenotypic characterization, the following antibodies were used: anti- measured as previously described [11] . After 3 days of co-culture, 5 µM doxorubicin, alone or in 451 the presence of the compounds, was added to the upper chamber of Transwell inserts containing 452 hCMEC/D3 cells monolayer. After 3 h, GB cells were collected from the lower chamber and the 453 intracellular amount of doxorubicin was measured spectrofluorimetrically as described above.
454
Cytotoxicity. The release of LDH in cell supernatant was measured as reported in [16] , using a for the activity of LDH, as described above. 
